Young-Onset Gastrointestinal Adenocarcinoma Incidence and Survival Trends in the Northern Territory, Australia, with Emphasis on Indigenous Peoples

Mia Shepherdson 1*, Shalem Leemaqz 2,3, Gurmeet Singh 4, Courtney Ryder 2,3,5, Shahid Ullah 2, Karla Canuto 6, Joanne P. Young 7,8,9, Timothy J. Price 7,8,9, Ross A. McKinnon 2,3*, Stephen J. Pandol 10*, Claire T. Roberts 2,3,* and Savio George Barreto 1,2,3,*

Abstract: Background and Aims: A concerning rise in incidence of young-onset cancers globally led to the examination of trends in incidence and survival of gastrointestinal (GI) adenocarcinomas in the Northern Territory (NT), Australia, over a 28-year period, with a special emphasis on Indigenous peoples. Methods: This cross-sectional analysis of a prospective longitudinal database, NT Cancer Registry (1990–2017), includes all reported cases of GI (oesophagus, stomach, small intestine, pancreas, colon, rectum, and rectum) adenocarcinomas over the last 3 decades in individuals aged >50 years, whilst the younger (18–50 years) cohort has remained unchanged with a (non-significant) trend towards an increase. There has been a significantly improved overall survival in both age cohorts. An insight into these trends amongst Australia’s Indigenous (who constitute 31% of the territory’s population) confirms that while the incidence was significantly lower in Indigenous patients compared to non-Indigenous patients, in both age cohorts, Indigenous patients had worse survival rates. This study calls for a concerted effort aimed at investigating the existence of modifiable sociodemographic factors underlying these disturbing trends. There is a need to enhance preventative strategies, as well as to improve the delivery of cancer care and its uptake amongst Indigenous peoples.

Simple Summary: This study from the Australian Northern Territory’s Cancer Registry data provides evidence for a significant decrease in incidence of gastrointestinal (oesophageal, stomach, small intestine, colon, rectum, and pancreas) adenocarcinomas over the last 3 decades in individuals aged >50 years, whilst the younger (18–50 years) cohort has remained unchanged with a (non-significant) trend towards an increase. There has been a significantly improved overall survival in both age cohorts. An insight into these trends amongst Australia’s Indigenous (who constitute 31% of the territory’s population) confirms that while the incidence was significantly lower in Indigenous patients compared to non-Indigenous patients, in both age cohorts, Indigenous patients had worse survival rates. This study calls for a concerted effort aimed at investigating the existence of modifiable sociodemographic factors underlying these disturbing trends. There is a need to enhance preventative strategies, as well as to improve the delivery of cancer care and its uptake amongst Indigenous peoples.
between 2010 and 2017 (HR = 0.45 (95%CI 0.29–0.72; \( p < 0.0007 \)) and HR = 0.64 (95%CI 0.52–0.78; \( p < 0.0001 \)), respectively) compared to 1990–1999, driven by an improvement in survival in colonic adenocarcinoma alone, as the survival remained unchanged in other GI subsites. The incidence was significantly lower in Indigenous patients compared to non-Indigenous patients, in both age cohorts (18–50 years IRR = 0.68 95% CI 0.51–0.91; \( p < 0.009 \) and >50 years IRR = 0.48 95% CI 0.40–0.57; \( p < 0.0001 \)). However, Indigenous patients had worse survival rates (18–50 years HR = 2.06 95% CI 1.36–3.11; \( p < 0.0007 \) and >50 years HR = 1.66 95% CI 1.32–2.08; \( p < 0.0001 \)). Conclusions: There is a trend towards an increased incidence of young-onset GI adenocarcinomas in the NT. Young Indigenous patients have lower incidence but worse survival across all GI subsites, highlighting significant health inequities in life expectancy. Targeted, culturally safe Indigenous community-focussed programs are needed for early detection and patient-centred management of GI adenocarcinomas.

**Keywords:** outcomes; morbidity; mortality; stomach; pancreas; colon; Indigenous

1. Introduction

Globally, there have been several reports of increasing incidence of early- or young-onset cancers [1–4]. Recently, we confirmed this disturbing trend over the past 28 years in South Australia by interrogating data from the South Australian Cancer Registry [5]. Early life events have long been suspected to play a role in the causation of young-onset cancers [6,7]. We proposed the Perinatal and Early Life Influences on CANcer (PELICan) hypothesis [8], providing supporting evidence from the literature, linking perinatal stressors that not only affect the epigenome, but also have an increased propensity to affect these children in their adolescent years, resulting in an increased risk of cancer. This can be further influenced by social determinants of health, which produce health inequities between populations. For example, higher cancer incidence rates have been observed in individuals living with a socioeconomic disadvantage [9,10].

Internationally, Indigenous peoples are the longest surviving civilisations on earth and continue to face significant health disparities and marginalisation across multiple social indicators (socioeconomic status, life expectancy, education) from ongoing colonisation [11–15]. In Australia, cancer inequities in outcomes are evident between Indigenous (Aboriginal and Torres Strait Islander) and non-Indigenous patients [16–20]. These disparities prompted the implementation of the National Aboriginal and Torres Strait Islander Cancer Framework in 2014 [21,22]. Given the compelling relationship between young-onset cancers and significant health inequities such as (lower) socioeconomic status, one of our aims was to explore inequity impacts in the incidence and survival of GI adenocarcinomas for Indigenous peoples in the NT. Indigenous Australians make up 3% of Australia’s population [23] but account for 31% of the NT population [24]. Understanding manifestations of inequity in young-onset cancer will provide much-needed insight into impacts on Australia’s Indigenous and provide critical understanding surrounding cancer preventative strategies (i.e., early detection), which have been created to improve the health of Indigenous Australians.

2. Materials and Methods

The NT Cancer Registry (NTCR) captures all NT cancer diagnosis and cancer-related deaths in accordance with the requirements of the NT Cancer Registration Act (last updated in 2011) [25], specifically, the reporting of all cancer cases to the registry. This activity includes information from treating physicians where the cause of death or patient demographics are incomplete. The registry provides a clinical epidemiological repository of cancers in the NT, to inform government initiatives, as well as established screening and prevention programs. A cross-sectional analysis, from 1 January 1990 to 31 December 2017, of prospectively collected longitudinal data was undertaken, focussing on all cases of adenocarcinoma: oesophagus, stomach, small intestine, pancreas, colon, and rectum.
Ethics approval for this study was obtained from the Aboriginal Ethics Sub-Committee (AESC) of the Human Research Ethics Committee of the NT Department of Health and Menzies School of Health Research (HREC) (HREC Reference Number: 2021-4043).

2.1. Selection of Cases

Inclusion Criteria

NT residents aged >18 years, with a pathologically confirmed diagnosis of GI adenocarcinoma; ICD-10-AM codes C15 oesophagus, C16 stomach, C17 small intestine, C25 pancreas, C18 colon (excluding C18.1), C19 rectosigmoid junction, C20 rectum. Histology codes for adenocarcinoma: ICD-10-AM 8140/2, 8140/3, 8141/3, 8143/3, 8210/2, 8210/3 and 8230/2.

The study period was categorised into 3 time periods (1990–1999, 2000–2009, 2010–2017) to reflect incidence and survivals of cancers over time.

2.2. Statistical Analysis

Statistical analyses were conducted using R version 4.1.1 (R Foundation for Statistical Computing, Vienna, Austria). Patients’ characteristics were expressed as median and interquartile range (IQR) for skewed data. The Mann–Whitney U test was used to explore the significance of differences in patients’ age between two groups of patients. Proportions were presented as percentages of the respective denominator and were compared between groups using a standard Chi-square test for association with continuity correction, where appropriate.

The incidence rates were calculated by taking the total number of cases divided by the population at risk. The rates were presented per 100,000 persons over 3 time periods for age groups 18–50 years and >50 years, for each sex, Indigenous status and cancer primary sites. Mid-interval population references for each time period were used as the denominator in the calculation of incidence rates. A Poisson regression model was applied to examine the incidence rates between groups of the above characteristics. The estimates were calculated using the likelihood ratio method and were expressed as incidence rate ratios (IRRs) from the Poisson model. The Poisson regression model was also used to calculate the average annual percentage change.

Survival was measured from the date of cancer diagnosis to the date of death, and individuals were censored at date of loss to follow-up or census date. The census date was assigned on 31 December 2017. The NTCR data are linked to the Births, Deaths, and Marriage data annually. Complete data were obtained on survival days, age of diagnosis, date of death, sex, primary sites, and Indigenous status. Cox proportional hazard models were applied to examine the survival outcomes. Sex, primary sites, Indigenous status, and cohort era were used to explore the risk of death between two cohorts (18–50 years and >50 years). The estimates were calculated using the likelihood ratio method and were expressed as hazard ratios (HRs); the lower the HR, the longer the survival. Proportional hazard assumption was tested by a log–log plot of survival and Schoenfeld Residuals. Survival curves for patient survival were evaluated by standard Kaplan–Meier survival curves, and patient cohorts were compared by log-rank test. The two-sided test was performed for all analyses, 95% confidence intervals were reported, and the level of significance was set at 5%.

3. Results

3.1. Patient Data and Overall Incidence and Survival Trends

A total of 1608 patients were diagnosed with oesophageal, stomach, small intestinal, pancreatic, or colorectal adenocarcinoma in the NT between 1990 and 2017 (298, 18.5% patients aged 18–50 years and 1310, 81.5% patients aged >50 years) (Table 1). Adenocarcinoma of the colon was the most commonly reported subsite involved in both age cohorts (27.2/100,000 for individuals aged 18–50 years and 900.3/100,000 for those aged >50 years).
Table 1. Patient’s characteristics, era, and primary sites of cancer between two age groups (n = 1608).

|                          | (18–50 Years) | (>50 Years) | p-Value |
|--------------------------|---------------|-------------|---------|
|                          | n = 298 (18.5%) | n = 1310 (81.5%) |         |
|                          | n %  | n %  |         |
| Age (years): median (IQR) | 45 (39–49) | 64 (58–72) | <0.0001 |
| Sex                      |     |     |         |
| Male                     | 172 57.7 | 834 63.7 | 0.07    |
| Female                   | 126 42.3 | 476 36.3 |         |
| Indigenous               |     |     | <0.0001 |
| Non-Indigenous           | 240 80.5 | 1179 90.0 |         |
| Indigenous               | 58 19.5 | 131 10.0 |         |
| Era                      |     |     | 0.4     |
| 1990–1999                | 72 24.2 | 275 21.0 |         |
| 2000–2009                | 103 34.6 | 501 38.2 |         |
| 2010–2017                | 123 41.3 | 534 40.8 |         |
| Primary site             |     |     | 0.0006  |
| Large intestine (excl. Appendix) | 147 49.3 | 704 53.7 |         |
| Rectum                   | 97 32.6 | 276 21.1 |         |
| Pancreas                 | 17 5.7 | 122 9.3 |         |
| Stomach                  | 19 6.4 | 108 8.2 |         |
| Oesophagus               | 12 4.0 | 81 6.2 |         |
| Small intestine          | 6 2.0 | 19 1.5 |         |

Note. Number and percentages are reported unless stated otherwise; IQR, interquartile range. P-values are based on Mann–Whitney U test for medians and Chi-square test for proportions.

Age, in itself, was a contributing factor for incidence, with a higher increment per year of age for individuals aged 18–50 years (IRR = 1.15 (95%CI 1.13–1.17; p < 0.0001)) as compared to those >50 years (IRR = 1.06 (95%CI 1.06–1.07; p < 0.0001)) (Table 2). The overall cancer incidence rates varied by sex for the >50 years cohort (131.1/100,000 for females and 196.9/100,000 for males >50 years) with IRR = 0.67 (95%CI 0.59–0.75; p < 0.0001). There was a significantly lower incidence of adenocarcinomas in every subsite for females in the >50 years cohort, except for pancreatic adenocarcinoma (Figure 1). In the 18–50 years cohort, no significant difference in incidence, by sex of the patient, was noted either in the overall cohort (4.4/100,000 for females and 5.4/100,000 for males aged 18–50 years; p = 0.09), or by organ subsite in the 18–50 years cohort (Table 2, Figures 1 and S1).

There was a significantly improved survival across all GI adenocarcinoma subsites over the 3 time cohorts (HR = 0.45 (95%CI 0.29–0.72; p = 0.0007)) for those aged 18–50 years and 0.64 (95%CI 0.52–0.78; p < 0.0001) for those >50 years, respectively, between 2010 and 2017 compared to years 1990 to 1999. Here also, females >50 years had a significantly improved survival compared to their male counterparts (HR = 0.84 (95%CI 0.72–0.98; p = 0.03)). No significant difference in survival was noted amongst females in the 18–50 years cohort (HR = 0.88 (95%CI 0.62–1.27; p = 0.5)).

The improvement in survival amongst the 18–50 years cohort was due only to a significantly improved survival for colonic adenocarcinoma in the last time period (HR = 0.46 (95%CI 0.22–0.98; p = 0.04)). On the contrary, in the >50 years cohort, the significantly improved survival was driven by improvements in survival in colonic (HR = 0.60 (95%CI 0.44–0.81; p = 0.0008)), oesophageal (HR = 0.41 (95%CI 0.20–0.84; p = 0.02)), and small intestinal (HR = 0.11 (95%CI 0.01–0.83; p = 0.03)) adenocarcinomas over the last time period (Figure 2).
**Table 2.** Incidence rates (IR) and incidence rate ratios (IRR) for age, sex, era, and cancer sites between two age groups (\(n = 1608\)).

| (\(<50\) Years) | (\(\geq50\) Years) |
|-----------------|------------------|
| \(n = 298\)     | \(n = 1310\)     |
| Overall         |                  |
| 95.64 (85.09, 107.14) | 1321.70 (1251.09, 1395.26) |
| Age (years)     |                  |
| 1.15 (1.13, 1.17) | <0.0001          |
| Sex             |                  |
| Male            |                  |
| 5.39 (4.09, 7.10) | Reference        |
| Female          |                  |
| 4.41 (3.31, 5.87) | 0.82 (0.65, 1.03) |
| Indigenous      |                  |
| Non-Indigenous  |                  |
| 5.91 (4.61, 7.56) | Reference        |
| Indigenous      |                  |
| 4.02 (2.87, 5.62) | 0.68 (0.51, 0.91) |
| Era             |                  |
| 1990–1999       |                  |
| 4.66 (3.40, 6.38) | Reference        |
| 2000–2009       |                  |
| 4.83 (3.56, 6.57) | 1.04 (0.77, 1.41) |
| 2010–2017       |                  |
| 5.14 (3.82, 6.90) | 1.10 (0.82, 1.48) |
| Cancer site     |                  |
| Large intestine |                  |
| 27.22 (21.68, 34.18) | -                |
| Rectum          |                  |
| 17.96 (13.91, 23.19) | 0.81             |
| Pancreas        |                  |
| 3.15 (1.91, 5.20)  | -                |
| Stomach         |                  |
| 3.52 (2.18, 5.67)  | -                |
| Oesophagus      |                  |
| 2.22 (1.23, 4.00)  | -                |
| Small intestine |                  |
| 1.11 (0.49, 2.51)  | -                |

*IR is incidence per 100,000 Northern Territory residents. IRRs were not reported for age, and IRRs were not reported for cancer sites.

**Figure 1.** Trend in incidence rates by Indigenous status, sex, and era between two age groups across cancer sites, 1990–2017 (\(n = 1608\)).

### 3.1. GI adenocarcinomas

#### Trends across Populations

The overall incidence rate for GI adenocarcinomas in individuals aged 18–50 years in the NT remained unchanged over the last three time periods from 1990–1999 to 2010–2017 (4.7/100,000 to 5.1/100,000), and the rates amongst individuals aged >50 years decreased over the same time period from 189.5/100,000 to 122.9/100,000 (IRR = 0.65 (95%CI 0.56–0.75); \(p < 0.0001\)) (Table 2). Cancer incidence rates for Indigenous peoples aged 18–50 years were 4.0/100,000 and 110.7/100,000 for >50 years of ages, which was significantly lower compared...
to non-Indigenous peoples, 5.9/100,000 (18–50 years) with IRR = 0.68 (95% CI 0.51–0.91) 
(p = 0.009) and 233/100,000 (>50 years) with IRR = 0.48 (95% CI 0.40–0.57) (p < 0.0001).

| Cohort         | Sites          | Groups          | HR (95% CI) | p-value |
|----------------|----------------|-----------------|-------------|---------|
| 18–50 years    | Large intestine| Male Reference  | 0.82 (0.47, 1.44) | 0.5     |
|                |                | Female          | 0.82 (0.47, 1.44) | 0.5     |
|                |                | Non-indigenous  | 0.22 (1.06, 4.64) | 0.03    |
|                |                | Indigenous      | 0.73 (0.38, 1.44) | 0.37    |
|                |                | 1990–1999       | 0.46 (0.22, 0.98) | 0.04    |
|                |                | 2000–2009       |              |         |
|                |                | 2010–2017       |              |         |
|                | Rectum         | Male Reference  | 0.53 (0.25, 1.16) | 0.11    |
|                |                | Female          | 0.53 (0.25, 1.16) | 0.11    |
|                |                | Non-indigenous  | 2.55 (1.13, 5.74) | 0.02    |
|                |                | Indigenous      | 0.74 (0.33, 1.68) | 0.47    |
|                |                | 1990–1999       | 0.47 (0.17, 1.29) | 0.15    |
|                |                | 2000–2009       |              |         |
|                |                | 2010–2017       |              |         |
|                | Pancreas       | Male Reference  | 1.40 (0.11, 18.24) | 0.8     |
|                |                | Female          | 1.40 (0.11, 18.24) | 0.8     |
|                |                | Non-indigenous  | 0.25 (0.01, 8.64) | 0.45    |
|                |                | Indigenous      | 0.59 (0.03, 13.03) | 0.74    |
|                |                | 1990–1999       | 0.21 (0.02, 2.73) | 0.23    |
|                |                | 2000–2009       |              |         |
|                |                | 2010–2017       |              |         |
|                | Stomach        | Male Reference  | 1.29 (0.13, 12.57) | 0.83    |
|                |                | Female          | 1.29 (0.13, 12.57) | 0.83    |
|                |                | Non-indigenous  | 6.30 (0.75, 53.27) | 0.09    |
|                |                | Indigenous      | 0.27 (0.03, 2.77) | 0.27    |
|                |                | 1990–1999       | 0.88 (0.18, 4.07) | 0.88    |
|                |                | 2000–2009       |              |         |
|                |                | 2010–2017       |              |         |
|                | Oesophagus      | Male Reference  |              |         |
|                |                | Female          |              |         |
|                |                | Non-indigenous  |              |         |
|                |                | Indigenous      |              |         |
|                |                | 1990–1999       |              |         |
|                |                | 2000–2009       |              |         |
|                |                | 2010–2017       |              |         |
|                | Small intestine | Male Reference  |              |         |
|                |                | Female          |              |         |
|                |                | Non-indigenous  |              |         |
|                |                | Indigenous      |              |         |
|                |                | 1990–1999       |              |         |
|                |                | 2000–2009       |              |         |
|                |                | 2010–2017       |              |         |

Figure 2. Hazard ratios (HR) and 95% CI (Cox proportional hazard model) for Indigenous status, sex, and era by primary sites between two age groups (n = 1668). * Reliable estimates of HR (95% CI) cannot be obtained for Oesophagus and Small intestine in 18–50 years due to small sample size.

The reduced overall incidence of GI adenocarcinomas noted amongst Indigenous peoples in both age cohorts was largely influenced by the significantly lower incidence of
colonic adenocarcinomas in the 18–50 years cohort (IRR = 0.51 (95%CI 0.32–0.79, p = 0.003)), and colonic and rectal adenocarcinomas in the >50 years cohort (IRR = 0.31 (95%CI 0.23–0.41, p < 0.0001); and (IRR = 0.38 (95%CI 0.25–0.59, p < 0.0001), respectively) (Figure 3 and Supplementary Table S2).

### Table 1: Incidence Rate Ratios (IRR) and 95% CI (Poisson regression model) for Indigenous Status, Sex, and Era by Primary Sites between two age groups (n = 1608).

| Cohort | Sites     | Groups   | IRR (95% CI) | p-value |
|--------|-----------|----------|-------------|---------|
| 18-50 years | Large intestine | Male | 1.03 (0.74, 1.42) | 0.87 |
|         |           | Female  | 1.00 (0.77, 1.28) | 1.00 |
|         |           | Non-indigenous | 0.51 (0.32, 0.79) | 0.003 |
|         |           | Indigenous | 1.00 (0.77, 1.28) | 1.00 |
|         |           | 1990-1999 | 0.80 (0.52, 1.23) | 0.32 |
|         |           | 2000-2009 | 0.95 (0.64, 1.43) | 0.62 |
|         |           | 2010-2017 | 0.65 (0.49, 0.89) | 0.04 |
|         | Rectum    | Male | 0.75 (0.46, 1.24) | 0.26 |
|         |           | Female  | 1.32 (0.77, 2.26) | 0.31 |
|         |           | 1990-1999 | 1.24 (0.73, 2.11) | 0.43 |
|         |           | 2000-2009 | 1.24 (0.73, 2.11) | 0.43 |
|         |           | 2010-2017 | 0.77 (0.45, 1.36) | 0.47 |
|         | Pancreas  | Male | 0.77 (0.46, 1.34) | 0.59 |
|         |           | Female  | 1.22 (0.74, 2.02) | 0.71 |
|         |           | 1990-1999 | 1.26 (0.79, 2.01) | 0.74 |
|         |           | 2000-2009 | 2.02 (0.54, 7.53) | 0.29 |
|         |           | 2010-2017 | 0.81 (0.47, 1.39) | 0.65 |
|         | Stomach   | Male | 0.78 (0.42, 1.47) | 0.60 |
|         |           | Female  | 1.26 (0.82, 1.93) | 0.25 |
|         |           | 1990-1999 | 0.84 (0.58, 1.28) | 0.62 |
|         |           | 2000-2009 | 1.96 (0.82, 4.68) | 0.25 |
|         |           | 2010-2017 | 1.96 (0.82, 4.68) | 0.25 |
|         | Oesophagus | Male | 0.22 (0.09, 0.52) | 0.05 |
|         |           | Female  | 0.95 (0.56, 1.61) | 0.93 |
|         |           | 1990-1999 | 0.74 (0.42, 1.35) | 0.72 |
|         |           | 2000-2009 | 1.31 (0.32, 5.33) | 0.70 |
|         |           | 2010-2017 | 1.31 (0.32, 5.33) | 0.70 |
|         | Small intestine | Male | 1.06 (0.62, 1.82) | 0.94 |
|         |           | Female  | 2.90 (1.38, 6.19) | 0.20 |
|         |           | 1990-1999 | 2.90 (1.38, 6.19) | 0.20 |
|         |           | 2000-2009 | 0.88 (0.05, 14.23) | 0.93 |
|         |           | 2010-2017 | 3.03 (0.34, 27.42) | 0.32 |
| >50 years | Large intestine | Male | 0.86 (0.74, 1.00) | 0.06 |
|         |           | Female  | 0.31 (0.23, 0.39) | <0.0001 |
|         |           | 1990-1999 | 1.07 (0.87, 1.30) | 0.52 |
|         |           | 2000-2009 | 0.72 (0.59, 0.89) | 0.002 |
|         |           | 2010-2017 | 0.45 (0.35, 0.59) | <0.0001 |
|         | Rectum    | Male | 0.97 (0.73, 1.30) | 0.19 |
|         |           | Female  | 1.20 (0.78, 1.84) | 0.41 |
|         |           | 1990-1999 | 0.87 (0.64, 1.18) | 0.38 |
|         |           | 2000-2009 | 0.52 (0.39, 0.71) | <0.0001 |
|         |           | 2010-2017 | 0.52 (0.39, 0.71) | <0.0001 |
|         | Pancreas  | Male | 0.79 (0.55, 1.13) | 0.19 |
|         |           | Female  | 1.20 (0.78, 1.84) | 0.41 |
|         |           | 1990-1999 | 0.60 (0.37, 0.99) | 0.04 |
|         |           | 2000-2009 | 0.87 (0.34, 1.02) | 0.05 |
|         |           | 2010-2017 | 0.45 (0.29, 0.71) | 0.0008 |
|         | Stomach   | Male | 0.47 (0.31, 0.71) | 0.0003 |
|         |           | Female  | 1.28 (0.82, 2.02) | 0.28 |
|         |           | 1990-1999 | 0.64 (0.38, 1.02) | 0.05 |
|         |           | 2000-2009 | 0.45 (0.29, 0.71) | 0.0008 |
|         | Oesophagus | Male | 0.18 (0.10, 0.34) | <0.0001 |
|         |           | Female  | 0.36 (0.16, 0.84) | 0.02 |
|         |           | 1990-1999 | 1.26 (0.67, 2.33) | 0.48 |
|         |           | 2000-2009 | 0.78 (0.42, 1.47) | 0.45 |
|         |           | 2010-2017 | 0.82 (0.33, 2.06) | 0.68 |
|         | Small intestine | Male | 0.82 (0.23, 2.83) | 0.76 |
|         |           | Female  | 0.82 (0.23, 2.83) | 0.76 |
|         |           | 1990-1999 | 1.83 (0.38, 8.81) | 0.45 |
|         |           | 2000-2009 | 1.69 (0.37, 7.73) | 0.50 |
|         |           | 2010-2017 | 1.69 (0.37, 7.73) | 0.50 |

Figure 3. Incidence rate ratios (IRR) and 95% CI (Poisson regression model) for Indigenous status, sex, and era by primary sites between two age groups (n = 1608).
Rates of GI adenocarcinomas increased per year in males 18–50 years, with an estimated average annual percentage change (AAPC) of 2.23% (95%CI 0.32–4.18; \( p = 0.02 \)). There was also an increasing trend for both non-Indigenous and Indigenous populations in 18–50 years, with the Indigenous population having a higher AAPC (AAPC 1.88 (95%CI 0.28–3.51; \( p = 0.02 \)) for non-Indigenous and AAPC 3.70 (95%CI 0.24–7.28; \( p = 0.04 \)) (Supplementary Table S1).

3.1.2. Survival by Time Trends and Site in Indigenous Compared to Non-Indigenous Peoples

Survival estimates from Kaplan–Meier plots revealed the greatest median survivals for rectal adenocarcinoma in 18–50 years (3.98 years) and colonic adenocarcinoma in >50 years (4.17 years) (Table 3). Using colonic adenocarcinoma as the reference, survival following pancreatic and stomach adenocarcinoma were significantly lower for those aged 18–50 years (HR = 2.30 (95%CI 1.19–4.46; \( p < 0.01 \)) and HR = 2.73 (95%CI 1.49–5.02; \( p < 0.001 \)), respectively. For those aged >50 years, survival following pancreatic (HR = 5.76 (95%CI 4.58–7.24; \( p < 0.0001 \)), stomach (HR = 2.91 (95%CI 2.28–3.70; \( p < 0.0001 \)), oesophageal (HR = 3.29 (95%CI 2.51–4.30; \( p < 0.0001 \)), and small intestinal (HR = 2.01 (95%CI 1.10–3.68; \( p < 0.02 \)) adenocarcinoma was significantly lower compared to the reference (Table 4 and Supplementary Figure S2).

Table 3. Median survival times (years) for primary sites of cancer between two age groups (\( n = 1608 \)).

| Cancer Sites | (18–50 Years) | (>50 Years) |
|--------------|---------------|-------------|
|              | \( n = 298 \) (18.5%) | \( n = 1310 \) (81.5%) |
| Median (95% CI) | Median (95% CI) |
| Overall | 3.37 (1.59–8.66) | 2.91 (1.24–7.46) |
| Large intestine | 3.75 (1.79–9.97) | 4.17 (1.75–8.45) |
| Rectum | 3.98 (1.90–9.62) | 4.06 (1.67–9.03) |
| Pancreas | 1.59 (0.97–5.59) | 0.98 (0.56–1.49) |
| Stomach | 1.51 (1.12–2.79) | 1.55 (0.85–2.81) |
| Oesophagus | 2.19 (1.56–3.56) | 1.64 (1.06–2.57) |
| Small intestine | 1.73 (0.80–4.19) | 1.86 (0.82–4.98) |

Table 4. Hazard ratios (HR) and 95% CI (Cox proportional hazard model) for age, sex, era, and cancer sites between two age groups (\( n = 1608 \)).

| (18–50 Years) | (>50 Years) |
|---------------|-------------|
| \( n = 298 \) | \( n = 1310 \) |
| HR (95% CI) | \( p \)-Value | HR (95% CI) | \( p \)-Value |
| Age (years) | 1.02 (1.00, 1.05) | 0.07 | 1.04 (1.03, 1.05) | <0.0001 |
| Sex | | | | |
| Male | | | | |
| Female | 0.88 (0.62, 1.27) | 0.5 | 0.84 (0.72, 0.98) | 0.03 |
| Indigenous | | | | |
| Non-Indigenous | Reference | | Reference | - |
| Indigenous | 2.06 (1.36, 3.11) | 0.0007 | 1.66 (1.32, 2.08) | <0.0001 |
| Era | | | | |
| 1990–1999 | Reference | | Reference | - |
| 2000–2009 | 0.63 (0.42, 0.97) | 0.03 | 0.81 (0.68, 0.97) | 0.02 |
| 2010–2017 | 0.45 (0.29, 0.72) | 0.0007 | 0.64 (0.52, 0.78) | <0.0001 |
| Cancer site | | | | |
| Large intestine | Reference | | Reference | - |
| Rectum | 0.94 (0.63, 1.42) | 0.78 | 1.01 (0.82, 1.23) | 0.95 |
| Pancreas | 2.30 (1.19, 4.46) | 0.01 | 5.76 (4.58, 7.24) | <0.0001 |
| Stomach | 2.73 (1.49, 5.02) | 0.001 | 2.91 (2.28, 3.70) | <0.0001 |
| Oesophagus | 1.87 (0.88, 3.98) | 0.1 | 3.29 (2.51, 4.30) | <0.0001 |
| Small intestine | 1.88 (0.59, 6.02) | 0.29 | 2.01 (1.10, 3.68) | 0.02 |
Survival, following GI adenocarcinomas, was significantly lower amongst Indigenous peoples as compared to non-Indigenous peoples in both age cohorts over the study period (HR = 2.06 (95%CI 1.36–3.11; p < 0.0007) for the 18–50 years cohort and HR = 1.66 (95%CI 1.32–2.08; p < 0.0001) for the >50 years cohort, respectively) (Table 4 and Supplementary Figure S2). The significantly reduced survival for Indigenous peoples was largely the effect of colonic and rectal adenocarcinoma in those aged 18–50 years (HR = 2.22 (95%CI 1.06–4.64; p < 0.03) and HR = 2.55 (95%CI 1.13–5.74; p < 0.02), respectively). For Indigenous people >50 years, reduced survival was largely the effect of colonic (HR = 0.72 (95%CI 1.19–2.48; p < 0.004)), pancreatic (HR = 1.84 (95%CI 1.17–2.89; p < 0.008)), and oesophageal (HR = 3.85 (95%CI 1.68–8.82; p < 0.001)) adenocarcinomas (Supplementary Table S3).

4. Discussion

Our research shares the incidence and survival of GI adenocarcinomas in NT residents over a 28-year period. The incidence of young-onset cancers (18–50 years) marginally, but not statistically significantly, increased (by 10%), while the incidence in the >50 years cohort significantly reduced. Male sex was associated with poorer prognosis in older age (>50 year), whereas young-onset cancers were non-discriminatory. Poorer survival outcomes were observed in Indigenous populations despite an overall lower incidence of GI adenocarcinomas, compared to non-Indigenous individuals. This is a novel finding for young-onset cancers.

Lifestyle and environmental factors such as obesity, diet, smoking, and alcohol exposure are well-documented risk factors for young-onset GI cancers [26–28]. The NT records the highest percentage of both daily smokers (20%) and alcohol consumers who exceed the recommended number of daily standard drinks (21.4%), compared to other states and territories in Australia. The association between rising smoking rates and the rise in tobacco-related cancers was reported in the NT nearly a decade ago [29]. Metabolic syndrome and its contributing factors of poor diet and sedentary lifestyle have been linked to early-onset solid-organ tumours [27,28]. Liu et al. [28] demonstrated a risk ratio of 1.2 for every 5-unit increment in body mass index (BMI) in young adults diagnosed with colorectal cancer. Over the past two decades, we have seen an increase in both obesity and young-onset cancers in the Australian population [30]. This suggests a temporal association of metabolic syndrome serving as a contributory factor to the rise in young-onset cancers. However, it does not explain the stable rate of late-onset cancers despite an increase in BMI in this age group, too. Although the incidence of GI adenocarcinomas is on the rise, improved survival has been demonstrated in our young-onset cohort. This finding is in contrast to our observations in young-onset adenocarcinomas in South Australia (where the overall survival across all subsites has remained unchanged) [5]. This trend has been attributed to the significantly improved survival in colonic adenocarcinoma, especially in the last time period. Improved survival in colonic adenocarcinoma may be credited to increasing awareness of young-onset cancers or timely access to imaging and colonoscopy. Additionally, the cancer surveillance programmes (colon, breast, and cervical) are incorporated as part of primary health care and specialist outreach services in the NT. Colon cancer is also likely to present earlier than stomach and pancreatic cancer, thus allowing for a variety of treatment options with less disease burden [31]. Improved colon cancer survival is unlikely related to screening in patients with a positive family history, as young-onset colorectal cancer is more commonly diagnosed in patients without a family history [32]. The lack of hereditary predisposition has also been noted in young-onset gastric and pancreatic cancers, suggesting young-onset cancers are the result of an alternate carcinogenic pathway [33–35]. For this reason, simply reducing the age of screening based on family history will likely increase the burden on the health care system without improving young-onset cancer survival significantly. However, a recent modelling study found that reducing the age for Aboriginal and Torres Strait Islander peoples would be cost-effective and save
more lives [36]. Additionally, investing resources into studying the cause of increased young-onset GI cancers may be more economical and beneficial for society in the long term.

Male gender has been consistently associated with greater incidence and poorer survival in GI cancers [37,38]. The Australian Bureau of Statistics reports that adult males are more likely to be obese and partake in higher rates of smoking and alcohol consumption compared to females [30,39,40]. It is therefore not surprising older males are at higher risk of developing and dying from GI cancers. Perhaps the most pertinent finding when analysing sex in our study was that the young-onset GI cancers did not discriminate between male and female patients. This may be partially explained by the PELiCan hypothesis [8] as exposure to perinatal stressors and carcinogens in utero would be equal amongst male and female foetuses. Unborn males would not be at an increased risk of GI cancers compared to females as smoking, obesity, and alcohol are male-dominated risk factors experienced later in life. The PELiCan hypothesis may also explain how the incidence of GI cancers was stable for the >50 years cohort but increasing for the 18–50 years cohort. Not only has obesity increased in the adult population, but also in the pregnant population, where currently 1 in 5 pregnant women are obese [41,42]. Obesity in pregnancy with its associated perinatal complications [43] may result in stress and/or inflammation-induced epigenetic changes in the foetus predisposing to obesity and young-onset cancer.

The impact of colonisation globally continues to impact the socioeconomic and health status and life expectancy for Indigenous populations as compared to non-Indigenous populations. Social determinants and lower socioeconomic status have been consistently associated with poor cancer survival [44,45]. In 2006, Anderson et al. [46] alarmingly reported that the life expectancy of Aboriginal and Torres Strait Islander peoples was 20 years lower than that for the total Australian population. The recent statistics from the Australian Institute of Health and Welfare [47] show improvements, but not parity. In 2015–2017, life expectancy at birth for Indigenous Australians was estimated to be 71.6 years for males and 75.6 years for females. In comparison, over the same period, life expectancy at birth for non-Indigenous Australians was 80.2 years for males and 83.4 years for females. Cancer survival was no exception to this health discrepancy, which prompted the Australian government to implement the National Aboriginal and Torres Strait Islander Cancer Framework in 2014 [21,22,48]. The results of our study are consistent with the literature whereby, despite a lower incidence of cancer, Indigenous patients had a significantly reduced survival in both age cohorts. These outcomes concur in part with research by Condon et al. [17], who also demonstrated poorer cancer survival amongst Indigenous peoples in the NT, with diagnoses at an advanced stage of the cancer being a contributing factor. Additionally, a previous study from South Australia has flagged issues around availability and access to surgical and systemic treatments amongst Aboriginal cancer patients compared to non-Aboriginal South Australian patients, which further complicated the disadvantages associated with geographic remoteness and advanced stage of disease at diagnosis, compounded by the presence of associated comorbid conditions [49]. In the present study, owing to the lack of stage-specific data, we are unable to comment on whether a delayed diagnosis was responsible for the poorer survival observed. Certainly, the significant health inequities that impact Indigenous Australians with ongoing marginalisation would be contributors to this trend [16]. Distance and access to tertiary health settings have been shown to contribute to later presentation and more advanced disease in Indigenous populations, along with health professionals in rural and remote settings being trained as generalists [18,50,51]. Not only is remoteness a likely impediment to regular, and timely, access to healthcare and poor overall cancer survival [52], but cultural marginalisation and access to culturally safe and responsive healthcare is also a compounding factor contributing to delayed disease presentations or delay in timely treatment [16,53]. Whilst underrepresentation of Indigenous status within registries remains an area of global concern [12,20], in the NT, there is good ascertainment of Indigenous status, as evidenced by no missing data in the NTCR data analysed in this study.
This study successfully reported the incidence and survival of GI adenocarcinoma in the NT and evaluated the influence of Indigenous status, age, and primary tumour location. Data were collected from the reputable NTCR. The use of three distinct time periods was effective in tracking changes in incidence and survival over time and allowed for a quick comparison to our previous South Australian study. The study could be further improved by data linkage, including data pertaining to patient socioeconomic status and premorbid baseline such as postcode, BMI, alcohol intake, and smoking status. Data linkage with national administrative and clinical datasets (e.g., Pharmaceutical Benefits Scheme/PBS and Medicare Benefits Schedule/MBS) will help provide pertinent information on costs incurred with the management of these cancers. Information on timely access to cancer treatment such as chemoradiotherapy or surgical management may help explain survival outcomes. Data stratification resulted in small cohort sample sizes, which limited the statistical power and ability to conduct an in-depth analysis on the significance of primary tumour location. Further studies with an increased sample size will likely yield information on the behaviour of different gastrointestinal cancers, which could influence current screening regimes. In order to capture data that appropriately record factors impacting on patient outcomes, data registries should engage with Aboriginal and Torres Strait Islander health bodies to broaden coding, to capture community needs, and work towards data sovereignty. Data that recognise and respond to the health and well-being concepts and needs of Australia’s First Peoples constitutes a step towards data sovereignty for Aboriginal and Torres Strait Islander communities [54,55]. An exemplar of this includes the Footprints in Time Study, with Indigenous leadership, oversight, and a focus on positive strength-based data collection and reporting [56].

5. Conclusions

Our study uniquely compares the incidence and survival in young-onset GI adenocarcinomas between Indigenous and non-Indigenous NT residents. This study demonstrates that not only are young-onset GI cancers increasing for residents aged 18–50 years, but there is a significant and disturbing trend of lower incidence but poorer survival for Indigenous residents of any age. Lifestyle and environmental factors during the perinatal period and into early adulthood are likely contributors to these phenomena; however, more research is imperative to identify at-risk cohorts.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/cancers14122870/s1. Table S1: Average annual percentage change, AAPC, (Poisson Regression Model) for gender, Indigenous status and primary sites of cancer between two age groups (n = 1608); Table S2: Incidence rate ratios (IRR) and 95% CI (Poisson regression model) for sex, Indigenous status and era by primary sites between two age groups (n = 1608); Table S3: Hazard ratios (HR) and 95% CI (Cox Proportional hazard model) for sex, Indigenous status and era by primary sites between two age groups (n = 1608); Supplementary Figure S1: Trend in incidence rates by sex, Indigenous status and era between two age groups across cancer sites 1990–2017 (n = 1608); Figure S2: Kaplan-Meier survival curves for sex, era, Indigenous status and primary sites between age groups.

Author Contributions: Conceptualisation, S.G.B.; Formal analysis, S.L. and G.S.; Investigation, M.S.; Methodology, S.G.B., M.S., S.L., C.R., S.J.P. and C.T.R.; Project administration, S.G.B. and C.R.; Software, S.L.; Supervision, S.G.B. and C.T.R.; Validation, S.U., K.C., J.P.Y., T.J.P., R.A.M. and S.J.P.; Writing—original draft, M.S.; Writing—review & editing, S.G.B., S.L., G.S., C.T.R., S.U., K.C., J.P.Y., T.J.P., R.A.M., S.J.P. and C.T.R. All authors have read and agreed to the published version of the manuscript.

Funding: RAM support: supported by the Beat Cancer Project funded by Cancer Council SA and SA Health. SP support—US NIH: R01 AA024464, P01 DK098108, P00 AA0119991, U01 DK108314, US DoD: W81XWH1910888. CTR support—National Health and Medical Research Council of Australia (NHMRC) Investigator Grant (GNT1174971) and a Matthew Flinders Professorial Fellowship from Flinders University, South Australia. SGB support—Flinders Foundation grant: 49358025.
Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki. Ethics approval for this study was obtained from the Aboriginal Ethics Sub-Committee (AESC) of the Human Research Ethics Committee of the NT Department of Health and Menzies School of Health Research (HREC) (HREC Reference Number: 2021-4043).

Informed Consent Statement: Since only non-identifiable data was provided to us by the NTCR, a waiver of consent was provided by the Ethics Committee.

Data Availability Statement: Authors are unable to provide this data owing to the Ethics approval being granted on the premise that the (Northern Territory Cancer Registry) data will not be released to a third party.

Acknowledgments: Shu Qin Li, Northern Territory Cancer Registrar, for her administrative support to this project.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Barreto, S.G.; Pandol, S.J. Young-Onset Carcinogenesis—The Potential Impact of Perinatal and Early Life Metabolic Influences on the Epigenome. *Front. Oncol.* 2021, 11, 653289. [CrossRef] [PubMed]
2. Done, J.Z.; Fang, S.H. Young-Onset Colorectal Cancer: A Review. *World J. Gastrointest. Oncol.* 2021, 13, 856–866. [CrossRef] [PubMed]
3. El Din, K.S.; Loree, J.; Sayre, E.C.; Gill, S.; Brown, C.; Dau, H.; De Vera, M.A. Trends in the epidemiology of young-onset colorectal cancer: A worldwide systematic review. *BMJ Cancer* 2020, 20, 288. [CrossRef]
4. di Martino, E.; Smith, L.; Bradley, S.H.; Hemphill, S.; Wright, J.; Renzi, C.; Bergin, R.; Emerj, J.; Neal, R.D. Incidence trends for twelve cancers in younger adults—A rapid review. *Br. J. Cancer* 2022, 126, 1374–1386. [CrossRef] [PubMed]
5. Schell, D.; Ullah, S.; Brooke-Smith, M.E.; Hollington, P.; Yeow, M.; Karapetis, C.S.; Watson, D.J.; Pandol, S.; Roberts, C.T.; Barreto, S.G. Gastrointestinal Adenocarcinoma Incidence and Survival Trends in South Australia, 1990–2017. *Cancers* 2022, 14, 275. [CrossRef] [PubMed]
6. Murphy, C.C.; Singal, A.G.; Baron, J.A.; Sandler, R.S. Decrease in Incidence of Young-Onset Colorectal Cancer Before Recent Increase. *Gastroenterology* 2018, 155, 1716–1719.e4. [CrossRef] [PubMed]
7. Rea, D.; Coppola, G.; Palma, G.; Barbieri, A.; Luciano, A.; Del Prete, P.; Rossetti, S.; Berretta, M.; Facchini, G.; Perdonà, S.; et al. Microangiota effects on cancer: From risks to therapies. *OncoTarget* 2018, 9, 17915–17927. [CrossRef]
8. Barreto, S.G. We Asked the Experts: Providing the Road Map to Uncovering the Pathophysiology of Young-Onset Cancer to Guide Treatment and Preventive Strategies. *World J. Surg.* 2020, 44, 3212–3213. [CrossRef] [PubMed]
9. Arık, A.; Dodd, E.; Cairns, A.; Streftaris, G. Socioeconomic disparities in cancer incidence and mortality in England and the impact of age-at-diagnosis on cancer mortality. *PLoS ONE* 2021, 16, e0253854. [CrossRef]
10. Hoebel, J.; Kroll, L.E.; Fiebig, J.; Lampert, T.; Katalinic, A.; Barnes, B.; Kraywinkel, K. Socioeconomic Inequalities in Total and Site-Specific Cancer Incidence in Germany: A Population-Based Registry Study. *Front. Oncol.* 2018, 8, 402. [CrossRef] [PubMed]
11. Australian Institute of Health and Welfare. *The Health and Welfare of Australia’s Aboriginal and Torres Strait Islander People, an Overview* 2011; Contract No Cat. No Ihw 42; AIHW: Canberra, Australia, 2011.
12. Ryder, C.; Mackean, T.; Hunter, K.; Towers, K.; Rogers, K.; Holland, A.J.A.; Ivers, R. Factors contributing to longer length of stay in Aboriginal and Torres Strait Islander children hospitalised for burn injury. *Inj. Epidemiol.* 2020, 7, 52. [CrossRef] [PubMed]
13. Devi, S. Native American health left out in the cold. *Lancet* 2011, 377, 1481–1482. [CrossRef]
14. Australian Institute of Health and Welfare. *Mortality and Life Expectancy of Indigenous Australians’ 2008 to 2012; Contract No Cat. No Ihw 42; AIHW: Canberra, Australia, 2014.
15. Hill, K.; Barker, B.; Vos, T. Excess Indigenous Mortality: Are Indigenous Australians More Severely Disadvantaged Than Other Indigenous Populations? *Int. J. Epidemiol.* 2007, 36, 580–589. [CrossRef]
16. Chong, A.; Roder, D. Exploring differences in survival from cancer among Indigenous and non-Indigenous Australians: Implications for health service delivery and research. *Asian Pac. J. Cancer Prev.* 2010, 11, 953–961. [PubMed]
17. Condon, J.R.; Barnes, T.; Armstrong, B.K.; Selva-Nayagam, S.; Elwood, J.M. Stage at diagnosis and cancer survival for Indigenous Australians in the Northern Territory. *Med. J. Aust.* 2005, 182, 272–280. [CrossRef] [PubMed]
18. Moore, S.P.; O’Rourke, P.K.; Mallitt, K.-A.; Garvey, G.; Green, A.C.; Coory, M.D.; Valery, P.C. Cancer incidence and mortality in Indigenous Australians in Queensland, 1997-2006. *Med. J. Aust.* 2010, 193, 590–593. [CrossRef] [PubMed]
19. Valery, P.C.; Coory, M.; Stirling, J.; Green, A. Cancer diagnosis, treatment, and survival in Indigenous and non-Indigenous Australians: A matched cohort study. *Lancet* 2006, 367, 1842–1848. [CrossRef]
20. Zhang, X.; Condon, J.R.; Rumbold, A.R.; Cunningham, J.; Roder, D.M. Estimating cancer incidence in Indigenous Australians. *Aust. N. Z. J. Public Health* 2011, 35, 477–485. [CrossRef] [PubMed]
21. Brands, J.; Garvey, G.; Anderson, K.; Cunningham, J.; Chynoweth, J.; Wallington, I.; Morris, B.; Knott, V.; Webster, S.; Kinsella, L.; et al. Development of a National Aboriginal and Torres Strait Islander Cancer Framework: A Shared Process to Guide Effective Policy and Practice. *Int. J. Environ. Res. Public Health* 2018, 15, 942. [CrossRef]
22. Condon, J.R.; Zhang, X.; Baade, P.; Griffiths, K.; Cunningham, J.; Roder, D.M.; Coory, M.; Jelfs, P.L.; Threlfall, T. Cancer survival for Aboriginal and Torres Strait Islander Australians: A national study of survival rates and excess mortality. *Popul. Health Metrics* **2014**, *12*, 1. [CrossRef]

23. Australian Institute of Health and Welfare. *Australia’s Health 2016*; Australia’s Health Series No. 15. Cat. No. AUS 199; AIHW: Canberra, Australia, 2016.

24. Australian Institute of Health and Welfare. *Profile of Indigenous Australians*; AIHW: Canberra, Australia, 2020.

25. Northern Territory Legislation. Cancer (Registration) Act. Available online: https://legislation.nt.gov.au/legislation/cancer-registration-act-2009 (accessed on 5 June 2022).

26. Breaue, G.; Ellis, U. Risk Factors Associated with Young-Onset Colorectal Adenomas and Cancer: A Systematic Review and Meta-Analysis of Observational Research. *Cancer Control* **2020**, *27*, 1073274820976670. [CrossRef] [PubMed]

27. Kim, N.H.; Jung, Y.S.; Yang, H.-J.; Park, S.-K.; Park, J.H.; Park, D.I.; Sohn, C.I. Prevalence of and Risk Factors for Colorectal Neoplasia in Asymptomatic Young Adults (20–39 Years Old). *Clin. Gastroenterol. Hepatol.* **2018**, *17*, 115–122. [CrossRef] [PubMed]

28. Liu, P.-H.; Wu, K.; Ng, K.; Zauber, A.G.; Nguyen, L.; Song, M.; He, X.; Fuchs, C.S.; Ogino, S.; Willett, W.C.; et al. Association of Obesity with Risk of Early-Onset Colorectal Cancer Among Women. *JAMA Oncol.* **2019**, *5*, 37–44. [CrossRef] [PubMed]

29. Laine Tay, E.E.; Guthridge, S.; Zhang, X. Preventable Cancers in the Northern Territory—A Snapshot. *Chronicle* **2010**, *17*, 2–3.

30. Australian Bureau of Statistics. Overweight and Obesity, Australia. Available online: https://www.abs.gov.au/statistics/health/health-conditions-and-risks/overweight-and-obesity/latest-release (accessed on 5 June 2022).

31. Chakrabarti, S.; Peterson, C.Y.; Sriram, D.; Mahipal, A. Early Stage Colon Cancer: Current Treatment Standards, Evolving Paradigms, and Future Directions. *World J. Gastroenterol.* **2020**, *12*, 808–832. [CrossRef] [PubMed]

32. Lee, J.; Kim, I.-H.; Kim, J.S.; Kim, S.W.; Kim, J.G.; Oh, S.T.; Kang, W.K.; Lee, M.A. Different clinical characteristics in sporadic young-age onset colorectal cancer. *Medicine* **2016**, *95*, e4840. [CrossRef] [PubMed]

33. Bergquist, J.; Leiting, J.L.; Habermann, E.B.; Cleary, S.; Kendrick, M.L.; Smoot, R.L.; Nagorney, D.M.; Truty, M.J.; Grotz, T.E. Early-onset gastric cancer is a distinct disease with worsrisome trends and oncogenic features. *Surgery* **2019**, *166*, 547–555. [CrossRef] [PubMed]

34. Piciucchi, M.; Capurso, G.; Valente, D.; Mahipal, A. Demographic, clinical, and pathological features of early onset pancreatic cancer. *Pancreatology* **2015**, *15*, 151–155. [CrossRef] [PubMed]

35. Ntala, C.; Debernardi, S.; Feakins, R.M.; Crnogorac-Jurcevic, T. Demographic, clinical, and pathological features of early onset pancreatic cancer patients. *BMC Gastroenterol.* **2018**, *18*, 139. [CrossRef] [PubMed]

36. Lew, J.-B.; Feletto, E.; Worthington, J.; Roder, D.; Canuto, K.; Miller, C.; D’Onise, K.; Cantell, K. The potential for tailored screening to reduce bowel cancer mortality for Aboriginal and Torres Strait Islander peoples in Australia: Modelling study. *J. Cancer Policy* **2022**, *32*, 100325. [CrossRef] [PubMed]

37. Paulson, E.C.; Wirtalla, C.; Armstrong, K.; Mahmoud, N.N. Gender Influences Treatment and Survival in Colorectal Cancer Surgery. *Dis. Colon Rectum* **2009**, *52*, 1982–1991. [CrossRef] [PubMed]

38. Majek, O.; Gondos, A.; Jansen, L.; Emrich, K.; Holleczek, B.; Katalinic, A.; Nennecke, A.; Eberle, A.; Brenner, H.; Gekid Cancer Registry. Early-onset gastric cancer is a distinct disease with worrisome trends and oncogenic features. *JAMA Oncol.* **2016**, *2*, 1775–1785. [CrossRef] [PubMed]

39. Australian Bureau of Statistics. Smoking. Available online: https://www.abs.gov.au/statistics/health/health-conditions-and-risks/smoking/latest-release#data-download (accessed on 5 June 2022).

40. Alcohol. Available online: https://www.abs.gov.au/statistics/health/health-conditions-and-risks/alcohol-consumption/latest-release (accessed on 5 June 2022).

41. National Health Survey: First Results: Overweight and Obesity. 4364.05.001. 2019. Available online: https://iepc.org.au/wp-content/uploads/2019/01/4364.05.001-national-health-survey-first-results-2017-18.pdf (accessed on 5 June 2022).

42. Ward, M.C.; Agarwal, A.; Bish, M.; James, R.; Faulks, F.; Pitson, J.; Yuen, N.; Mnatzaganian, G. Trends in obesity and impact on obstetric outcomes in a regional hospital in Victoria, Australia. *Aust. N. Z. J. Obstet. Gynaecol.* **2019**, *60*, 204–211. [CrossRef]

43. McCall, S.J.; Li, Z.; Kurinczuk, J.J.; Sullivan, E.; Knight, M. Binational Cohort Study Comparing the Management and Outcomes of Pregnant Women with a BMI > 50–59.9 Kg/m(2) and Those with a BMI ≥ 60 Kg/m(2). *BMJ Open* **2018**, *5*, e021055. [CrossRef] [PubMed]

44. Chu, Q.D.; Hsieh, M.-C.; Gibbs, J.F.; Wu, X.-C. Social determinants of health associated with poor outcome for rural patients following resected pancreatic cancer. *J. Gastrointest. Oncol.* **2021**, *12*, 2567–2578. [CrossRef] [PubMed]

45. Dhahri, A.; Kaplan, J.; Naqvi, S.M.H.; Brownstein, N.C.; Ntiri, S.O.; Imanirad, I.; Felder, S.J.; Dineen, S.P.; Sanchez, J.; Dessureault, S.; et al. The impact of socioeconomic status on survival in stage III colon cancer patients: A retrospective cohort study using the SEER census-tract dataset. *Cancer Med.* **2021**, *10*, 5643–5652. [CrossRef] [PubMed]

46. Anderson, I.; Crengle, S.; Kamaka, M.L.; Chen, T.H.; Palafoux, N.; Jackson-Pulver, L. Indigenous Health in Australia, New Zealand, and the Pacific. *Lancet* **2006**, *367*, 1775–1785. [CrossRef]

47. Australian Government. Australian Institute of Health and Welfare. Indigenous Life Expectancy and Deaths. Available online: https://www.aihw.gov.au/reports/australias-health/indigenous-life-expectancy-and-deaths (accessed on 9 April 2022).
48. Moore, S.P.; Antoni, S.; Colquhoun, A.; Healy, B.; Ellison-Loschmann, L.; Potter, J.D.; Garvey, G.; Bray, F. Cancer Incidence in Indigenous People in Australia, New Zealand, Canada, and the USA: A Comparative Population-Based Study. *Lancet Oncol.* 2015, 16, 1483–1492. [CrossRef]

49. Banham, D.; Roder, D.; Eckert, M.; Howard, N.J.; Canuto, K.; Brown, A. Cancer treatment and the risk of cancer death among Aboriginal and non-Aboriginal South Australians: Analysis of a matched cohort study. *BMC Health Serv. Res.* 2019, 19, 771. [CrossRef]

50. Diaz, A.; Whop, L.J.; Valery, P.C.; Moore, S.P.; Cunningham, J.; Garvey, G.; Condon, J.R. Cancer outcomes for Aboriginal and Torres Strait Islander Australians in rural and remote areas. *Aust. J. Rural Health* 2015, 23, 4–18. [CrossRef]

51. Cunningham, J.; Rumbold, A.R.; Zhang, X.; Condon, J. Incidence, aetiology, and outcomes of cancer in Indigenous peoples in Australia. *Lancet Oncol.* 2008, 9, 585–595. [CrossRef]

52. Siegel, J.; Engelhardt, K.E.; Hornor, M.A.; Morgan, K.A.; Lancaster, W.P. Travel distance and its interaction with patient and hospital factors in pancreas cancer care. *Am. J. Surg.* 2020, 221, 819–825. [CrossRef] [PubMed]

53. Moore, S.P.; Green, A.C.; Bray, F.; Garvey, G.; Coory, M.; Martin, J.; Valery, P.C. Survival disparities in Australia: An analysis of patterns of care and comorbidities among indigenous and non-indigenous cancer patients. *BMC Cancer* 2014, 14, 517. [CrossRef] [PubMed]

54. Walter, M. The Voice of Indigenous Data: Beyond the Markers of Disadvantage. *Griffith Rev.* 2018, 60, 256.

55. Walter, M.; Suina, M. Indigenous data, indigenous methodologies and indigenous data sovereignty. *Int. J. Soc. Res. Methodol.* 2018, 22, 233–243. [CrossRef]

56. Salmon, M.; Skelton, F.; Thurber, K.A.; Bennetts Kneebone, L.; Gosling, J.; Lovett, R.; Walter, M. Intergenerational and Early Life Influences on the Well-Being of Australian Aboriginal and Torres Strait Islander Children: Overview and Selected Findings from Footprints in Time, the Longitudinal Study of Indigenous Children. *J. Dev. Orig. Health Dis.* 2019, 10, 17–23. [CrossRef]